← Back to Clinical Trials
Recruiting NCT06772701

NCT06772701 Validation of the French Version of the Edinburgh Postnatal Depression Scale (EPDS) Postnatally in the Father

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06772701
Status Recruiting
Phase
Sponsor Groupe Hospitalier du Havre
Condition Depression, Postpartum
Study Type INTERVENTIONAL
Enrollment 1,000 participants
Start Date 2024-07-11
Primary Completion 2027-01-12

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Mini International Neuropsychiatric InterviewEPDS book

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,000 participants in total. It began in 2024-07-11 with a primary completion date of 2027-01-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In recent years, fatherhood has changed considerably. Fathers are now more involved during the perinatal period, with their partner but also in caring for the child. Investigators now know that this period is also a source of major psychological upheaval, identity crisis, apprehension and anxiety for men. These upheavals can lead to depression that must be detected and treated as early as possible. This is an easy screening to perform using the EPDS (Edinburgh Postnatal Depression Scale). Currently, the EPDS is the most widely used self-questionnaire to assess the risk of depression in women during the perinatal period. Indeed, it is systematically recommended in many countries. It is starting to be used for the same purpose in the perinatal period in men, although the scale has not been validated in a representative sample of men in the pre- or post-natal period. The main objective is to validate the use of the EPDS scale as a screening tool for postnatal depression in a population of French fathers. They complete the PH-Q9, EPDS and socio-demographic questionnaires online at inclusion and 6 to 8 weeks after the birth of their child. Fathers included at the maternity ward also too Mini International Neuropsychiatric Interview (MINI) at inclusion.

Eligibility Criteria

Inclusion Criteria: * All fathers whose baby is 10 days old or less Exclusion Criteria: * People with a poor understanding of spoken or written French * Minors * Persons under court protection, guardianship or curatorship

Contact & Investigator

Central Contact

Angélique PICARD, project coordinator

✉ angelique.picard@ch-havre.fr

📞 +33232734856

Frequently Asked Questions

Who can join the NCT06772701 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Depression, Postpartum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06772701 currently recruiting?

Yes, NCT06772701 is actively recruiting participants. Contact the research team at angelique.picard@ch-havre.fr for enrollment information.

Where is the NCT06772701 trial being conducted?

This trial is being conducted at Clamart, France, Montivilliers, France.

Who is sponsoring the NCT06772701 clinical trial?

NCT06772701 is sponsored by Groupe Hospitalier du Havre. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology